Track topics on Twitter Track topics that are important to you
Constellation Healthcare Technologies (LON:CHT), the US-focused medical billing services specialist, has unveiled its fifth deal since listing – the acquisition of VEGA Medical Professionals for up to US$24mln in cash and shares. The purchase is expected to be earnings enhancing in its first full year with EBITDA expected increase from US$800,000 at the last results to around US$7mln within 24 months thanks to the synergies between the two businesses. A specialist in hospital based billing, VEGA has offices in New York, New Jersey, Texas, and Pennsylvania. The nuts and bolts of the acquisition are that 78% will be paid out in cash from Constellation’s reserves and debt facility, with remainder satisfied in shares. The takeover is subject to an earn-out agreement and VEGA hitting certain financial targets. Financially, VEGA is in the same order of its last acquisition – MRDX Medical Billing, which cost an initial US$28mln. Both are part of a buy and build strategy that will help consolidate the fragmented US medical billing sector. “The acquisition of VEGA provides further evidence of CHT's ability to identify and acquire quality businesses that have significant operational synergies that are accretive to our shareholders,” said chief executive Paul Parmar.
Original Article: Constellation Healthcare bags VEGA in US$24mln dealNEXT ARTICLE
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...